Elix Discovery & Tohoku University Team Up to Revolutionize Drug Discovery with AI
Elix Discovery, an AI drug discovery company, has joined forces with Tohoku University's Graduate School of Life Sciences to advance drug discovery using AI technologies. The joint research aims to accelerate ligand discovery for Targeted Protein Degradation (TPD) and propose new therapeutic strategies for intractable diseases.
Elix, focusing on small-molecular PROTACs and TPD, seeks to tackle traditionally 'undruggable' proteins. Their AI drug discovery platform, Elix DiscoveryTM, supports both Ligand-Based Drug Design (LBDD) and Structure-Based Drug Design (SBDD), enabling exploration across a broader range of approaches.
In this collaboration, Elix will work with Minoru Ishikawa's research group to develop compounds that act on targets critical to cellular homeostasis. This could provide valuable insights into biological functions and expand therapeutic possibilities. Elix's intuitive graphical user interface can automatically construct predictive models for optimal compound profiles, accelerating the drug discovery process.
Elix Discovery, with its innovative AI platform and focus on TPD, is poised to revolutionize drug discovery. Through its collaboration with Tohoku University, Elix aims to accelerate ligand discovery and propose new therapeutic strategies for intractable diseases, potentially leading to more effective treatments for patients.
